Molecular Partners AG
(NASDAQ : MOLN)

( )
MOLN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.27%176.780.0%$746.14m
AMGNAmgen, Inc. 1.08%251.081.5%$612.30m
VRTXVertex Pharmaceuticals, Inc. 3.74%305.531.9%$437.49m
GILDGilead Sciences, Inc. 5.16%66.211.0%$435.11m
REGNRegeneron Pharmaceuticals, Inc. 2.32%643.292.6%$372.05m
ILMNIllumina, Inc. 8.77%226.593.3%$330.40m
SNSSSunesis Pharmaceuticals, Inc. 5.74%4.420.7%$308.97m
NVAXNovavax, Inc. 2.00%42.3075.7%$284.25m
BIIBBiogen, Inc. 0.63%222.381.8%$205.32m
BNTXBioNTech SE 1.33%162.480.0%$158.03m
GOVXGeoVax Labs, Inc. 1.59%2.550.0%$140.51m
BMRNBioMarin Pharmaceutical, Inc. 1.97%96.944.2%$104.96m
CRSPCRISPR Therapeutics AG 1.88%80.140.6%$104.75m
PACBPacific Biosciences of California, Inc. -4.89%8.366.2%$98.27m
MRTXMirati Therapeutics, Inc. -0.06%86.321.6%$96.84m

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.